Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Recruiting

Phase 3

Glufosfamide vs. 5-FUGlufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Sponsor:

Eleison Pharmaceuticals LLC.

Code:

NCT01954992

Conditions

Metastatic Pancreatic Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Glufosfamide

Fluorouracil

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Eleison Pharmaceuticals LLC. on 2024-12-31.